Filing Details

Accession Number:
0001209191-23-056548
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-22 19:45:34
Reporting Period:
2023-11-21
Accepted Time:
2023-11-22 19:45:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1641281 Bolt Biotherapeutics Inc. BOLT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1227162 Edgar Engleman C/O Bolt Biotherapeutics, Inc.
900 Chesapeake Drive
Redwood City CA 94063
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-11-21 1,707 $0.90 1,952,302 No 4 S Indirect By Vivo Capital Fund VIII, L.P.
Common Stock Disposition 2023-11-21 236 $0.90 269,587 No 4 S Indirect By Vivo Capital Surplus Fund VIII, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Vivo Capital Fund VIII, L.P.
No 4 S Indirect By Vivo Capital Surplus Fund VIII, L.P.
Footnotes
  1. The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.903, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4.
  2. The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
  3. The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.